National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

dacarbazine
A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:Biocarbazine
Dacarbazina
Dacarbazina Almirall
Dacarbazine - DTIC
Dakarbazin
Dimethyl (triazeno) imidazolecarboxamide
Dimethyl Triazeno Imidazol Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Imidazole Carboxamide
Imidazole Carboxamide Dimethyltriazeno
US brand name:DTIC-Dome
Foreign brand names:Asercit
Dacatic
Deticene
Detimedac
Fauldetic
Abbreviations:DIC
DTIC
Code name:WR-139007
Chemical structure names:
  • 1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-
  • 5-(3-3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
  • 5-(dimethyltriazeno)imidazole-4-carboxamide
  • 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide



Previous:Cytoxan, D-cycloserine, D-methionine formulation MRX-1024, D1/3-MAGE-3-His fusion protein, DAB389 epidermal growth factor
Next:dacetuzumab, daclizumab, Dacogen, dactinomycin, dalteparin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov